accountcompany from shrinking.�� Therefore, the company���s main problem remains the same one facing Sanofi-Aventis, GlaxoSmithKline, and Eli Lilly: the paucity of new drugs coming out of company labs. In order to make the declining sales of the established...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Analyst Argues A Pfizer Break-Up Wouldn't Work
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account